Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Antibodies to Epstein-Barr virus and neurotropic viruses in multiple sclerosis and optic neuritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. MAIT cell subtypes in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Perfluorinated substances, risk factors for multiple sclerosis and cellular immune activation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LTα and TGFβ1 response

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Biomarkers of inflammation and epithelial barrier function in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Poul Erik H Jensen
  • Clemens Warnke
  • Kathleen Ingenhoven
  • Luca Piccoli
  • Marcia Gasis
  • Christina Hermanrud
  • Blanca M Fernandez-Rodriguez
  • Malin Ryner
  • Daniel Kramer
  • Jenny Link
  • Ryan Ramanujam
  • Michael Auer
  • Dorothea Buck
  • Verena Grummel
  • Elisa Bertotti
  • Nicolas Fissolo
  • Begoña Oliver-Martos
  • Petra Nytrova
  • Michael Khalil
  • Michael Guger
  • Sandra Rathmaier
  • Claudia Sievers-Stober
  • Raija L P Lindberg
  • Signe Hässler
  • Delphine Bachelet
  • Orhan Aktas
  • Naoimh Donnellan
  • Andy Lawton
  • Bernhard Hemmer
  • Eva Kubala Havrdova
  • Bernd Kieseier
  • Hans-Peter Hartung
  • Manuel Comabella
  • Xavier Montalban
  • Tobias Derfuss
  • Finn Sellebjerg
  • Pierre Dönnes
  • Marc Pallardy
  • Sebastian Spindeldreher
  • Philippe Broët
  • Florian Deisenhammer
  • Anna Fogdell-Hahn
  • Per Soelberg Sorensen
  • ABIRISK Consortium
Vis graf over relationer

Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.

OriginalsprogEngelsk
TidsskriftJournal of Neuroimmunology
Vol/bind326
Sider (fra-til)19-27
Antal sider9
ISSN0165-5728
DOI
StatusUdgivet - 15 jan. 2019

Bibliografisk note

Copyright © 2018 Elsevier B.V. All rights reserved.

ID: 58577830